Clinical Trials Logo
  1. Home
  2. Skin Infection
  3. NCT01593761

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus — CG400549  

Skin Infection Clinical Trial

Official title:
Phase 2a, Repeated-dose, Open-label, Single-arm Study of CG400549 for the Treatment of Complicated Acute Bacterial Skin and Skin Structure Infection (cABSSSI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)

Clinical Trial Summary

Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA. Secondary Objective(s): - To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due to MRSA - To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549. - To assess the safety of multiple doses of CG400459

Clinical Trial Description

This will be an open-label, exploratory study to evaluate the safety, pharmacokinetics, and efficacy of CG400549, daily for 10 to 14 days, in subjects with cABSSSI (major cutaneous abscesses) due to MRSA. All subjects will receive active treatment. Subjects will begin study treatment upon confirmation of clinical eligibility (ie, confirmation of MRSA infection is not required pretreatment). Subjects who begin treatment with CG400549 and are subsequently not found to have S. aureus infection will be discontinued from study treatment, treated as appropriate for the identified pathogen(s), and followed for safety. These subjects will be included in the safety analyses but not in the primary efficacy analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01593761
Study type Interventional
Source CrystalGenomics, Inc.
Contact
Status Completed
Phase Phase 2
Start date June 2012
Completion date October 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT03929224 - The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown Phase 4
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT06149117 - Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China Phase 4
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Recruiting NCT03131843 - Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination Phase 3
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Terminated NCT03372941 - Hospital Avoidance Strategies for ABSSSI Phase 4
Completed NCT02512614 - Evaluation of Novel Antimicrobial Hand Towels Phase 2/Phase 3
Not yet recruiting NCT06247761 - STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery N/A
Not yet recruiting NCT06170983 - Skin Inflammation and PK of Azithromycin N/A
Completed NCT02052388 - Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Phase 2
Completed NCT00619710 - Complicated Skin and Skin Structure Infections Phase 3
Recruiting NCT05339802 - A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections Phase 2
Completed NCT06087809 - Improving Short Course Treatment for Common Pediatric Infections N/A
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4